Frankfurt
30.03.26 | 15:25
25,800 Euro
-3,01 % -0,800
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 26,000 | 26,400 | 30.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nanobiotix im Fokus: Quartalszahlen als Bewährungsprobe für Krebs-Nanotechnologie | - | Investing.com Deutsch | ||
| Mo | Nanobiotix S.A.: NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | 6 | GlobeNewswire (USA) | ||
| Do | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 | 3 | GlobeNewswire (USA) | ||
| Mi | Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process | 1 | Benzinga.com | ||
| Mi | Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up | 2 | RTTNews | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Mi | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mi | Nanobiotix S.A.: NANOBIOTIX Statement Regarding Recent Media Speculation | 846 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches... ► Artikel lesen | |
| Mi | Nanobiotix-Aktie springt nach Bericht über mögliches Übernahmeinteresse von J&J | 20 | Investing.com Deutsch | ||
| Mi | Nanobiotix gains after report on J&J buyout bid | 5 | Seeking Alpha | ||
| 12.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 12.03. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 12.03. | Nanobiotix stock maintains Buy rating at TD Cowen on trial outlook | 2 | Investing.com | ||
| 17.02. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 9 | GlobeNewswire (USA) | ||
| 13.01. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 7 | GlobeNewswire (USA) | ||
| 17.12.25 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 9 | GlobeNewswire (USA) | ||
| 15.12.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.12.25 | Nanobiotix S.A.: NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris | 351 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen | |
| 01.12.25 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.11.25 | Leerink Partners raises Nanobiotix stock price target to $26 on pipeline progress | 2 | Investing.com | ||
| 24.11.25 | Nanobiotix S.A. provides Q3 Operational and Financial Update | 2 | Seeking Alpha |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 105,68 | +0,27 % | Argus hebt Illumina-Kursziel wegen neuer Produkte auf 145 US-Dollar an | ||
| PALATIN TECHNOLOGIES | 18,650 | -11,19 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRAIN BIOTECH | 2,460 | +1,23 % | BRAIN BIOTECH AG: Stabilität als strategische Phase | ||
| OCUGEN | 1,543 | +0,75 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| TEMPUS AI | 37,200 | +0,54 % | Tempus AI Enters Collaboration With Daiichi Sankyo | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Tempus AI announced a strategic collaboration with Daiichi Sankyo (4568.T) for accelerating the clinical development and differentiation of an antibody drug... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 0,770 | -0,65 % | COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on the development of natural... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,113 | +1,62 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 53,64 | -1,03 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves TECVAYLI in Combination with DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma | FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care... ► Artikel lesen | |
| IMMUNITYBIO | 5,774 | -0,59 % | ImmunityBio-Aktie -21%: Buy the dip? | Es ist eine nervenaufreibende Woche für ImmunityBio-Aktionäre. Nachdem der Kurs des Biotech-Unternehmens am Montag +10% in die Höhe schoss, ging es am gestrigen Dienstag um atemberaubende -21% nach... ► Artikel lesen | |
| XOMA ROYALTY | 25,600 | -0,78 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,055 | -0,50 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,823 | -1,53 % | AbCellera auf dem KeyBanc Forum: Strategische Fortschritte im Biotech-Sektor | ||
| GUARDANT HEALTH | 76,00 | +1,01 % | Krebs-Impfstoff: Chance Teil 2: Phase-2-Start für den Brustkrebs-Impfstoff und starke CAR-T-Daten bei Eierstockkrebs.Wird 2026 der Wendepunkt? | ||
| CYTOMX THERAPEUTICS | 3,824 | -0,31 % | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | ||
| GLOW LIFETECH | 0,028 | +1,82 % | Glow Lifetech Corp.: Glow Lifetech Reduces Over 41 Million Warrants and 5 Million Options, Strengthening Capital Structure; All $0.05 Warrants Now Expired | Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce a significant reduction in its outstanding... ► Artikel lesen |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,800 Euro und damit -3,01 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.